KENACORT 40 mg/ml sospensione iniettabile, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio, Lidocaína B. Braun 20 mg/ml solución inyectable, BUPIVACAÍNA PHYSAN 0,25% SOLUCIÓN INYECTABLE
TRAPEZIUS
Approved small_molecule active
Quick answer
KENACORT 40 mg/ml sospensione iniettabile, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio, Lidocaína B. Braun 20 mg/ml solución inyectable, BUPIVACAÍNA PHYSAN 0,25% SOLUCIÓN INYECTABLE for TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS is a Approved program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- TRAPEZIUS MYOFASCIAL SYNDROME IN FIBROMYALGIA PATIENTS
- Phase
- Approved
- Modality
- small_molecule
- Status
- active